The latest Investing Matters Podcast episode featuring financial educator and author Jared Dillian has been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksN4 Pharma Plc Share News (N4P)

Share Price Information for N4 Pharma Plc (N4P)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 0.80
Bid: 0.75
Ask: 0.85
Change: 0.00 (0.00%)
Spread: 0.10 (13.333%)
Open: 0.80
High: 0.80
Low: 0.80
Prev. Close: 0.80
N4P Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

TRADING UPDATES: N4 Pharma hails "encouraging" siRNA research

Thu, 07th Dec 2023 18:28

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

----------

Wentworth Resources PLC - Tanzania-focused natural gas production company - Etablissements Maurel & Prom SA, a Paris-based, energy industry-focused company, says it is moving closer to acquiring Wentworth. Explains that it has signed an agreement with the Tanzania Petroleum Development Corporation, which is structured as a 'call option' and allows Tanzania Petroleum to increase its ownership in the production interest by up to 20%. Wentworth has arranged for the Jersey Court to consider and possibly sanction the scheme at a hearing on December 19. Following this date, M&P will take ownership of Wentworth and acquire its 32% direct and indirect interest in Mnazi Bay. Subsequent to the closing of the Acquisition, M&P expects Tanzania Petroleum this call option, meaning that M&P will hold a 60% ownership in Mnazi Bay, and Tanzania Petroleum will hold 40%. M&P says the joint operating agreement will be changed to reflect these new partnership conditions. Adds that it will fund the acquisition with the GBP63 millio placed in escrow.

----------

N4 Pharma PLC - Derbyshire-based specialist pharmaceutical company focused on a delivery system for oncology, gene therapy and vaccines - Says that its work-to-date on its ongoing in vitro small interfering ribonucleic acid research, or siRNA, is "very encouraging", and shows that Nuvec has "considerable potential" to be able to knockdown two independent pathways leading to "more effective "cancer treatments. Explains that it has been investigating the ability of Nuvec nanoparticles to be loaded with, and deliver at the same time, two different siRNA known to inhibit relevant oncology targets. After confirming dual loading of Nuvec, N4 then tested the effect of BRD4 combined with EGFR and PLK1 combined with EGFR on knockdown and cell viability. Says that when when loaded together there was an interaction which resulted in a reduction in knockdown of EGFR receptor, though the reduction on cell viability was retained. It is now exploring varying the amount of each siRNA loaded on Nuvec, and also looking at how low the dose can be reduced to still achieve a functional cell inhibition endpoint. In terms of strategy moving forwards, says that that the precise combinations of siRNA, both in terms of target and concentration of siRNA, will vary depending in which cell type they are tested in.

----------

Software Circle PLC - Manchester-based printing and software company - Regarding the sale of Works Manchester Ltd, says that Works Manchester has filed a notice of intention to appoint administrators. This follows an earlier announcement in June, when Software said it had not received the first instalment of deferred consideration from Rymack Sign Solutions Ltd to buy Works Manchester. Further, due to reduced confidence of receiving payment of any deferred consideration from Rymack, the carrying value of the GBP2.81 million due under the sale and purchase agreement has been reduced to GBP350,000. Software is in the process of taking steps to recover the sums due, and says it will update the market again in due course. Adds that the Nettl Systems management team have been making arrangements with alternative suppliers so that continuity of supply is in place for products available through the Nettl Systems platform.

----------

Ecofin US Renewables Infrastructure Trust PLC - Investor in US renewable energy assets - Expects its Whirlwind Energy wind asset in in Floydada, Texas to reenergise in mid-December, after moving "significantly closer" to coming back online. Says that AEP, the owner of the Matador and Paducah substations, has now finished testing a new transmission line past Matador to Paducah. Adds that the first payment on its business interruption coverage has now been received and further payments are scheduled to follow, "substantially mitigating lost revenue". Meanwhile, the Ellis Road solar farm in Westminster, Massachusetts is back online, following a rodent infestation. Finally, says that progress continues to be made on a previously announced strategic review. Says there can be no certainty as to the outcome of the review or any asset sale process, nor whether any potential transaction or transactions arising could be successfully completed.

----------

By Holly Beveridge, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2023 Alliance News Ltd. All Rights Reserved.

More News
15 Jul 2022 11:21

AIM WINNERS & LOSERS: Fevertree lowers guidance; DP Poland sales rise

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Friday.

Read more
17 Mar 2022 16:28

UK shareholder meetings calendar - next 7 days

Friday 18 March  
Caracal Gold PLCAGM
Chenavari Toro Income Fund LtdAGM
Monday 21 March 
Aferian PLCAGM
Altona Rare Earths PLCAGM
Helical PLCGM re becoming REIT & buyback
Inland Homes PLCAGM
Tuesday 22 March 
Crest Nicholson Holdings PLCAGM
Hochschild Mining PLCEGM re Amarillo Gold acquisition
Hydro Hotel Eastbourne PLCAGM
Starvest PLCAGM
Sureserve Group plcAGM
Wynnstay Group PLCAGM
Wednesday 23 March 
CML Microsystems PLCGM re employee share plans
Quartix Technologies PLCAGM
Strategic Equity Capital PLCGM re: tender offer
Thursday 24 March 
BlackRock Throgmorton Trust PLCAGM
Independent Investment Trust PLCAGM
N4 Pharma PLCAGM
React Group PLCAGM
  
Copyright 2022 Alliance News Limited. All Rights Reserved.

Read more
23 Feb 2022 14:54

IN BRIEF: N4 Pharma falls as loss widens and Nuvec tests inconclusive

N4 Pharma PLC - Derbyshire, England-based pharmaceutical company - Reports a pretax loss of GBP1.8 million for 2021, widening 18% from GBP1.6 million the previous year. Says year focused on in vivo studies of Nuvec, a delivery system for cancer treatments and vaccines, which did not return any "meaningful" immunological response in studies carried out by Hamburg-based drug development company Evotec SE. Says that on the back of increased data the company can now narrow its focus on the oncology and gene therapy market.

Read more
31 Jan 2022 22:06

TRADING UPDATES: Hiro plans acquisition vehicle IPO; Aquila reviews

TRADING UPDATES: Hiro plans acquisition vehicle IPO; Aquila reviews

Read more
25 Jan 2022 19:12

TRADING UPDATES: Cordiant raises GBP200 million; Home REIT spends

TRADING UPDATES: Cordiant raises GBP200 million; Home REIT spends

Read more
25 Jan 2022 14:50

N4 Pharma outlines work plan after 'encouraging' data

(Sharecast News) - Specialist treatment and vaccine delivery system developer N4 Pharma updated the market on its work plan on Tuesday, following "encouraging data" from its oncology research as announced on 13 December.

Read more
13 Dec 2021 21:57

IN BRIEF: N4 Pharma to focus resources on gene therapy

IN BRIEF: N4 Pharma to focus resources on gene therapy

Read more
13 Dec 2021 14:56

N4 upbeat on cancer treatment progress, vaccine disappoints

(Sharecast News) - Cancer treatment and vaccine delivery system developer N4 Pharma updated the market on data from its proof-of-concept programmes and ongoing activities on Monday.

Read more
1 Nov 2021 06:57

IN BRIEF: Kings Arms Yard VCT appoints two new non-executive directors

IN BRIEF: Kings Arms Yard VCT appoints two new non-executive directors

Read more
1 Oct 2021 09:35

N4 Pharma granted Europe patent with China equivalent on its way

(Sharecast News) - Specialist pharmaceutical company N4 Pharma announced on Friday that it has been granted a patent for its 'Nuvec' cancer treatment and vaccine delivery system by the European Patent Office (EPO), specifically around its composition, particulate materials, and methods for making the particulate materials.

Read more
1 Oct 2021 08:50

N4 Pharma secures patent in Europe for Nuvec, expects China to follow

N4 Pharma secures patent in Europe for Nuvec, expects China to follow

Read more
20 Sep 2021 12:02

TRADING UPDATES: Christie Group and Open Orphan swing to profit

TRADING UPDATES: Christie Group and Open Orphan swing to profit

Read more
14 Sep 2021 14:31

TRADING UPDATES: Boku launches in Germany; Focusrite trading well

TRADING UPDATES: Boku launches in Germany; Focusrite trading well

Read more
24 Aug 2021 12:35

TRADING UPDATES: IG Design starts year well; Ilika in Stereax progress

TRADING UPDATES: IG Design starts year well; Ilika in Stereax progress

Read more
20 May 2021 19:22

TRADING UPDATES: Gamma tips 2021 revenue jump; Smart Metering progress

TRADING UPDATES: Gamma tips 2021 revenue jump; Smart Metering progress

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.